Pharyngitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:27:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pharyngitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Testing benzydamine hydrochloride and dichlorobenzyl alcohol lozenges for relief of sore throat symptoms in patients with acute pharyngitis https://clinicaltrials.eu/trial/testing-benzydamine-hydrochloride-and-dichlorobenzyl-alcohol-lozenges-for-relief-of-sore-throat-symptoms-in-patients-with-acute-pharyngitis/ Wed, 29 Apr 2026 15:07:58 +0000 https://clinicaltrials.eu/trial/testing-benzydamine-hydrochloride-and-dichlorobenzyl-alcohol-lozenges-for-relief-of-sore-throat-symptoms-in-patients-with-acute-pharyngitis/ This study examines acute pharyngitis, which is an inflammation of the throat that causes soreness and discomfort. The study will test lozenges containing two active substances: benzydamine hydrochloride and 2,4 dichlorobenzyl alcohol. These substances work together to reduce inflammation and provide local numbing effects in the throat. The study will compare these lozenges with another product already available on the market and with placebo. The purpose of this study is to determine how well the lozenges work in relieving symptoms of acute pharyngitis and to assess their safety.

Participants in this study will be adults who have recently developed acute pharyngitis with significant throat soreness that started within the last 30 hours. The study is designed so that neither the participants nor the researchers know which treatment is being given during the trial. Each person will receive lozenges to dissolve slowly in the mouth. The treatment will last for up to 4 days, during which participants will need to use an electronic device such as a smartphone or tablet to record information about their symptoms.

The main focus of the study is to measure how much the throat soreness improves during the first 2 hours after taking the first lozenge. Researchers will track changes in throat pain intensity by comparing the new lozenges with both placebo and the existing market product. All three types of lozenges are taken in the same way, by placing them in the mouth and allowing them to dissolve slowly. The maximum daily dose is 25.2 milligrams, and the total amount used over the treatment period will not exceed 84 milligrams.

]]> Study of benzydamine hydrochloride and dichlorobenzyl alcohol lozenges for treating acute pharyngitis symptoms https://clinicaltrials.eu/trial/study-of-benzydamine-hydrochloride-and-dichlorobenzyl-alcohol-lozenges-for-treating-acute-pharyngitis-symptoms/ Wed, 29 Apr 2026 15:07:30 +0000 https://clinicaltrials.eu/trial/study-of-benzydamine-hydrochloride-and-dichlorobenzyl-alcohol-lozenges-for-treating-acute-pharyngitis-symptoms/ This clinical trial focuses on testing lozenges containing benzydamine hydrochloride and 2,4-dichlorobenzyl alcohol for treating acute pharyngitis, which is a condition causing throat inflammation and soreness. The study aims to determine if these lozenges are effective in providing symptom relief for people with acute throat inflammation.

The study will compare three different treatments: DoriDuo lozenges (containing both active ingredients), Mebocaína Anti-Inflam lozenges (containing the same active ingredients), and a placebo. The medications will be given as throat lozenges that dissolve in the mouth. The maximum daily dose will be 25.2 mg, and the treatment will last up to 4 weeks.

During the study, participants will take the assigned lozenges and have their throat soreness levels monitored, particularly in the first two hours after taking the medication. The study is designed to show whether the new medication works better than the placebo and is at least as effective as the existing treatment. All medications will be given in a way that neither the patients nor the doctors know which treatment is being used.

]]>